October 2023 - MediaMedic

IDweek2023 | Antimicrobial Utilization in Transplant Patients: A Deep Dive into Benchmarked Data

By Peter W. PENG 2023.10.27

IDweek2023 Antimicrobial Utilization in Transplant Patients: A Deep Dive into Benchmarked Data Transplant patients, encompassing those who undergo bone marrow transplants (BMT), allogeneic transplants, autologous transplants, and CAR-T procedures, represent a particularly vulnerable subgroup of the population because of their immunocompromised status. The medical management of these patients involves careful monitoring and appropriate utilization of antimicrobial agents to prevent potential infections and ensure optimal health outcomes.

IDweek2023 | A Comprehensive Examination of Racial, Ethnic, and Gender Disparities in Sepsis Treatment and Outcomes

By Peter W. PENG 2023.10.27

IDweek2023 A Comprehensive Examination of Racial, Ethnic, and Gender Disparities in Sepsis Treatment and Outcomes Sepsis, an extreme response to infection that can lead to life-threatening organ dysfunction, poses a significant global health issue. Despite advancements in healthcare, disparities in the treatment and outcomes of sepsis persist, particularly in relation to race, ethnicity, and gender. This article aims to shed light on these disparities, explore the potential underlying causes, and discuss the implications for healthcare providers and patients.

IDweek2023 | A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

By Peter W. PENG 2023.10.27

IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals IDweek2023 A Comprehensive Review of Outcomes in Intravenous to Oral Antimicrobial Therapy in Uncomplicated β-hemolytic Streptococcus Bloodstream Infections in Immunocompromised Individuals

IDweek2023 | A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment

By Peter W. PENG 2023.10.27

IDweek2023 A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment In the relentless battle against HIV, the advent of antiretroviral therapy (ART) has marked a significant turning point. The development and introduction of drug regimens have revolutionized HIV treatment, transforming HIV from a fatal illness into a manageable chronic condition. However, the dynamic nature of the virus and its ability to develop resistance to drugs necessitates continuous research into new treatment strategies.

IDweek2023 | The Revolutionary Shift in HIV Management: An In-Depth Analysis of Cabotegravir + Rilpivirine Long-Acting Treatment Versus Traditional Oral Antiretroviral Therapy

By Peter W. PENG 2023.10.27

IDweek2023 The Revolutionary Shift in HIV Management: An In-Depth Analysis of Cabotegravir + Rilpivirine Long-Acting Treatment Versus Traditional Oral Antiretroviral Therapy In the ever-evolving world of medicine, the ultimate goal has consistently been to enhance patient adherence and improve treatment outcomes. This is particularly apparent in the management of HIV, where antiretroviral therapy (ART) has been the cornerstone of treatment for many years. However, with the development of long-acting ART, there has been a dramatic shift in the landscape of HIV management. This comprehensive article delves into a detailed analysis of the real-world adherence and persistence of Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) compared to oral ART among people living with HIV (PWH) in the United States. This analysis is based on the ABOVE Study, conducted by a team of researchers and healthcare professionals from ViiV Healthcare and Analysis Group, Inc.

IDweek2023 | Exploring the Consequences of Low-Level Viremia Among Women with HIV

By Peter W. PENG 2023.10.27

IDweek2023 Exploring the Consequences of Low-Level Viremia Among Women with HIV Understanding the dynamics of HIV infection is critical for managing and controlling the disease. A vital aspect of this understanding is the awareness of Low-Level Viremia (LLV), a condition experienced by about a third of people living with HIV. Despite its prevalence, there is a significant gap in clinical guidance on how to counsel and manage individuals with LLV.

IDweek2023 | Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy’s Role

By Peter W. PENG 2023.10.27

IDweek2023 Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy's Role Hepatitis B, a viral infection that primarily affects the liver, can lead to serious complications, such as cirrhosis and hepatocellular carcinoma. In individuals living with HIV, the situation is further complicated since they face the risk of Hepatitis B reactivation - a condition that can occur when switching to antiretroviral therapy (ART) lacking Hepatitis B activity. This comprehensive article explores this complex medical phenomenon, providing a detailed understanding of its causative factors, implications, and potential strategies for patient management.

IDweek2023 | A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial

By Peter W. PENG 2023.10.27

IDweek2023A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial The approval of the long-acting injectable cabotegravir-rilpivirine in January 2021 marked a significant milestone in the medical realm. This dual-drug regimen has revolutionized the approach to HIV treatment by providing an effective and convenient alternative to daily oral medications. However, the question of how to best optimize access to this therapy in our clinics was an issue that required immediate attention. Consequently, a hypothesis was developed suggesting that cabotegravir-rilpivirine could be safely and effectively administered in a person’s own home, paving the way for an innovative study to test this theory.

IDweek2023 | A Deep Dive into the Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Insights from the OPERA® Cohort.

By Peter W. PENG 2023.10.27

IDweek2023 A Deep Dive into the Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Insights from the OPERA® Cohort. The world of HIV (Human Immunodeficiency Virus) management has seen remarkable strides over the years, with the advent of antiretroviral therapy (ART) significantly improving the quality of life for people living with the virus. One of the groundbreaking developments in this field is the emergence of long-acting injectable antiretroviral regimens, offering a unique approach to maintaining viral suppression and alleviating the burden of daily oral medication.

IDweek2023 | Understanding Post-Acute Sequelae of SARS-CoV-2 Infection: A Comprehensive Overview

By Peter W. PENG 2023.10.27

IDweek2023 Understanding Post-Acute Sequelae of SARS-CoV-2 Infection: A Comprehensive Overview The COVID-19 pandemic caused by the SARS-CoV-2 virus has had a significant impact on global health. While much attention has been given to the acute phase of the infection, there is emerging recognition of a subset of individuals experiencing persistent symptoms beyond the acute stage, known as Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). In this article, we explore the medical aspects of PASC, including its clinical manifestations, prevalence, potential underlying mechanisms, and implications for different age groups and sexes.